[go: up one dir, main page]

BE2011C028I2 - Macrocyclic analogs and methods of their use and preparation - Google Patents

Macrocyclic analogs and methods of their use and preparation

Info

Publication number
BE2011C028I2
BE2011C028I2 BE2011C028C BE2011C028C BE2011C028I2 BE 2011C028 I2 BE2011C028 I2 BE 2011C028I2 BE 2011C028 C BE2011C028 C BE 2011C028C BE 2011C028 C BE2011C028 C BE 2011C028C BE 2011C028 I2 BE2011C028 I2 BE 2011C028I2
Authority
BE
Belgium
Prior art keywords
preparation
methods
macrocyclic analogs
analogs
macrocyclic
Prior art date
Application number
BE2011C028C
Other languages
French (fr)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2011C028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BE2011C028I2 publication Critical patent/BE2011C028I2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a compound having the formula: that is useful as an intermediate in the preparation of certain pharmaceutically active halichondrin analogs.
BE2011C028C 1998-06-17 2011-09-02 Macrocyclic analogs and methods of their use and preparation BE2011C028I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation
EP99928746A EP1087960B1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (1)

Publication Number Publication Date
BE2011C028I2 true BE2011C028I2 (en) 2018-08-24

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C028C BE2011C028I2 (en) 1998-06-17 2011-09-02 Macrocyclic analogs and methods of their use and preparation

Country Status (22)

Country Link
US (4) US6214865B1 (en)
EP (4) EP2277873B1 (en)
JP (1) JP4454151B2 (en)
KR (1) KR100798600B1 (en)
CN (1) CN1216051C (en)
AT (1) ATE502932T1 (en)
AU (1) AU762998B2 (en)
BE (1) BE2011C028I2 (en)
BR (1) BRPI9911326B8 (en)
CA (3) CA2755266C (en)
CY (2) CY1111516T1 (en)
DE (2) DE69943296D1 (en)
DK (1) DK1087960T3 (en)
FR (1) FR11C0038I2 (en)
HU (1) HU227912B1 (en)
IL (1) IL139960A0 (en)
LU (1) LU91854I2 (en)
NO (5) NO328280B1 (en)
NZ (1) NZ508597A (en)
PT (1) PT1087960E (en)
WO (1) WO1999065894A1 (en)
ZA (1) ZA200007159B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (en) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 Macrocyclic analogs and their use and methods of preparation
DE10037310A1 (en) * 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
NZ555951A (en) 2002-03-22 2009-01-31 Eisai Co Ltd Hemiasterlin derivatives and uses thereof
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
CA2526385C (en) * 2003-05-29 2008-07-22 Abbott Laboratories Continuous dosing regimen with abt-751
EP1653953A4 (en) * 2003-07-29 2010-05-05 Eisai R&D Man Co Ltd Drug delivery methods and devices
CN1993342A (en) * 2004-06-03 2007-07-04 卫材株式会社 Intermediates for the preparation of halichondrin b
RS54054B1 (en) 2004-06-03 2015-10-30 Eisai R&D Management Co. Ltd. INTERMEDIATES FOR THE PREPARATION OF HALIHONDRIN B
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (en) * 2004-12-09 2008-07-03 エーザイ株式会社 Screening for tubulin isotypes in cancer treatment using halichondrin B analogs
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
CN102056930B (en) * 2008-04-04 2016-04-20 卫材R&D管理有限公司 halichondrin B analogs
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
RU2476216C1 (en) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Liposomal composition
DK2415470T3 (en) 2009-03-30 2016-09-19 Eisai R&D Man Co Ltd liposome
JP5556811B2 (en) * 2009-04-14 2014-07-23 日産化学工業株式会社 Method for producing tetrahydropyran compound
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
ES2731653T3 (en) 2011-03-18 2019-11-18 Eisai R&D Man Co Ltd Methods and uses to predict the response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013078559A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (en) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． Process for preparing 3-((2S, 5S) -4-methylene-5- (3-oxopropyl) tetrahydrofuran-2-yl) propanol derivatives and useful intermediates thereof
CN104080793B (en) * 2011-12-29 2017-09-19 阿方拉研究股份有限公司 2 (base of (2S, 3S, 4R, 5R) 5 (hydroxyl of (S) 3 amino 2 the third 1 base) 4 methoxyl group 3 (benzenesulfonylmethyl) tetrahydrofuran 2) acetaldehyde derivatives and their preparation method
CA2868627C (en) 2012-03-30 2021-02-16 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
KR20150090921A (en) 2012-12-04 2015-08-06 에자이 알앤드디 매니지먼트 가부시키가이샤 Use of Eribulin in the Treatment of Breast Cancer
AR096238A1 (en) 2013-05-15 2015-12-16 Alphora Res Inc PROCESS TO PREPARE DERIVATIVES OF 3 - ((2S, 5S) -4-METHYLENE-5- (3-OXOPROPIL) TETRAHYDROFURAN-2-IL) PROPANOL AND INTERMEDIARIES USEFUL FOR THE SAME
ES2705698T3 (en) 2013-06-26 2019-03-26 Eisai R&D Man Co Ltd Combination therapy for cancer treatment comprising eribulin and lenvatinib
CN105431438A (en) * 2013-07-03 2016-03-23 阿方拉研究股份有限公司 Synthetic method for preparing macrocyclic C1-keto analogs of halichondrin B and intermediates useful therein, including intermediates containing -SO2-(p-tolyl) group
CN103483352A (en) * 2013-10-18 2014-01-01 李友香 Medicinal bulk drug for resisting tumors
WO2015066729A1 (en) 2013-11-04 2015-05-07 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (en) 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd USEFUL METHODS IN THE SYNTHESIS OF HALICHONDRIN B ANALOGUES.
CN104860978A (en) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 Synthesis intermediates of halichondrin B analog
TW201617326A (en) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
BR112016026545A8 (en) * 2014-05-28 2021-07-06 Eisai R&D Man Co Ltd eribulin or a pharmaceutically acceptable salt thereof, its uses and kit for use in the treatment of breast cancer
JP2017520586A (en) * 2014-06-30 2017-07-27 プレジデント アンド フェローズ オブ ハーバード カレッジ Synthesis and use of halichondrin analogues
JP6659554B2 (en) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 High purity quinoline derivative and method for producing the same
US10208058B2 (en) * 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (en) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 Intermediate for preparing eribulin and preparation method thereof
LT3263106T (en) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. METHOD OF REDUCING BITTERNESS OF QUINOLINE DERIVATIVES
KR20170122810A (en) 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 A combination of PD-1 antagonist and eribulin for treating cancer
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
WO2016179607A1 (en) * 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
US10676481B2 (en) 2016-02-12 2020-06-09 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
WO2017188350A1 (en) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for inhibiting tumor growth
US11059799B2 (en) 2016-05-26 2021-07-13 Dr. Reddy's Laboratories Limited. Process for preparation of eribulin and intermediates thereof
KR102404629B1 (en) 2016-06-30 2022-06-02 에자이 알앤드디 매니지먼트 가부시키가이샤 Prince Reaction and Intermediates Useful for Synthesis of Halicondine Macrolides and Analogs thereof
AU2017342462A1 (en) 2016-10-14 2019-05-02 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (en) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ Palladium-mediated ketolization
JP2020511404A (en) * 2016-11-23 2020-04-16 ドクター レディズ ラボラトリーズ リミテッド Method for preparing eribulin and intermediates thereof
KR101991710B1 (en) 2017-12-14 2019-06-21 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
WO2018124847A1 (en) 2017-01-02 2018-07-05 연성정밀화학(주) Production intermediate of eribulin mesylate, and method for producing same
KR101880939B1 (en) 2017-01-02 2018-08-17 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same
CN108341738B (en) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
CN108341828B (en) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 Process for the preparation of eribulin and intermediates thereof
CN110072528B (en) 2017-02-08 2022-04-26 卫材R&D管理有限公司 Pharmaceutical composition for treating tumor
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
TWI863657B (en) 2017-04-05 2024-11-21 哈佛大學校長及研究員協會 Macrocyclic compound and uses thereof
KR20200013644A (en) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 Treatment of Hepatocellular Carcinoma
ES2940688T3 (en) 2017-07-06 2023-05-10 Harvard College Halichondrin synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (en) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 Intermediate for preparing eribulin and preparation method thereof
KR102177992B1 (en) 2017-11-09 2020-11-12 연성정밀화학(주) Intermediate for Preparing Eribulin Mesylate and Process for Preparing the Same
EP3710454B1 (en) 2017-11-15 2024-01-03 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en) 2017-11-21 2019-05-31 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
JP7469226B2 (en) 2018-01-03 2024-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 The Prins reaction and compounds useful for the synthesis of halichondrin macrolides and their analogues
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
EP3823973A4 (en) * 2018-07-20 2022-09-21 Dr. Reddy's Laboratories Limited PURIFICATION PROCESSES FOR THE MANUFACTURE OF ERIBULIN AND INTERMEDIATE PRODUCTS THEREOF
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US12522611B2 (en) * 2018-11-28 2026-01-13 Natco Pharma Limited Process for the preparation of high pure Eribulin and its Mesylate salt
AU2019404572B2 (en) 2018-12-20 2025-08-21 Auransa Inc. Analogues of pentamidine and uses therefor
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en) 2019-06-21 2020-12-24 Council Of Scientific And Industrial Research A chemo-enzymatic process for the preparation of homopropargylic alcohol
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3159541A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (en) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 Preparation method of eribulin and intermediate thereof
KR20220130160A (en) * 2020-01-22 2022-09-26 상하이 센후이 메디슨 컴퍼니 리미티드 Drug conjugates of eribulin derivatives, methods for preparing them, and uses thereof in the medical field
KR102377262B1 (en) 2020-05-11 2022-03-22 연성정밀화학(주) Crystalline Eribulin Salt
IL279168B (en) * 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd Process for the preparation of eribulin
CN113354659B (en) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 Synthesis of eribulin mesylate
CN117460540A (en) * 2021-07-22 2024-01-26 上海森辉医药有限公司 Drug conjugates of eribulin derivatives
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
IL322106A (en) * 2023-01-17 2025-09-01 Systimmune Inc Conjugate of eribulin drug
CN121311508A (en) 2023-06-09 2026-01-09 徕特康(苏州)生物制药有限公司 Anti-HER 2 complementary bispecific antibody-drug conjugate and preparation method and application thereof
CN118834221B (en) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 A halichondrin B analogue
WO2025081063A2 (en) 2023-10-13 2025-04-17 Eisai R&D Management Co., Ltd. Antibody-drug conjugate metabolites
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (en) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 Eribulin derivative and antibody-drug conjugate thereof, and medical use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
JP4454151B2 (en) * 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 Macrocyclic analogs and their use and methods of preparation
RS54054B1 (en) 2004-06-03 2015-10-30 Eisai R&D Management Co. Ltd. INTERMEDIATES FOR THE PREPARATION OF HALIHONDRIN B
EP2200992B1 (en) 2007-10-03 2014-02-26 Eisai R&D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
BRPI0820519A2 (en) 2007-11-16 2017-05-23 Eisai R&D Man Co Ltd intermediate for the synthesis of the halicondrin b analogue and desulfonylation reaction used for the intermediate
CN102056930B (en) 2008-04-04 2016-04-20 卫材R&D管理有限公司 halichondrin B analogs
SG182612A1 (en) 2010-01-26 2012-08-30 Eisai R&D Man Co Ltd Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Also Published As

Publication number Publication date
DE122011100031I1 (en) 2011-12-15
EP2272839B1 (en) 2012-08-22
DE69943296D1 (en) 2011-05-05
ZA200007159B (en) 2001-12-04
WO1999065894A1 (en) 1999-12-23
AU762998B2 (en) 2003-07-10
KR100798600B1 (en) 2008-01-28
US6214865B1 (en) 2001-04-10
CN1312804A (en) 2001-09-12
NO2011026I1 (en) 2012-01-09
RU2245335C2 (en) 2005-01-27
PT1087960E (en) 2011-06-17
HUP0103357A3 (en) 2002-10-28
ATE502932T1 (en) 2011-04-15
CA2335300A1 (en) 1999-12-23
JP2002518384A (en) 2002-06-25
AU762998C (en) 2000-01-05
FR11C0038I1 (en) 2011-10-14
LU91854I2 (en) 2011-10-17
US8148554B2 (en) 2012-04-03
US6469182B1 (en) 2002-10-22
NO328280B1 (en) 2010-01-25
EP1087960B1 (en) 2011-03-23
DK1087960T3 (en) 2011-06-14
FR11C0038I2 (en) 2013-01-11
NO2011018I1 (en) 2011-09-26
EP1087960A4 (en) 2004-12-01
CA2632433A1 (en) 1999-12-23
CN1216051C (en) 2005-08-24
EP2272839A1 (en) 2011-01-12
BR9911326B1 (en) 2015-01-06
EP1087960A1 (en) 2001-04-04
AU4573999A (en) 2000-01-05
CY1111516T1 (en) 2014-04-09
NO20006316D0 (en) 2000-12-12
NO2022019I1 (en) 2022-06-03
CY2011010I2 (en) 2014-04-09
KR20010083050A (en) 2001-08-31
HUP0103357A2 (en) 2002-01-28
IL139960A0 (en) 2002-02-10
US6365759B1 (en) 2002-04-02
JP4454151B2 (en) 2010-04-21
HU227912B1 (en) 2012-05-29
CA2632433C (en) 2012-02-07
CA2755266A1 (en) 1999-12-23
US20110172446A1 (en) 2011-07-14
NO20006316L (en) 2001-02-15
EP2277873B1 (en) 2012-05-30
EP2272840A1 (en) 2011-01-12
NZ508597A (en) 2004-01-30
EP2277873A1 (en) 2011-01-26
CA2755266C (en) 2014-08-12
NO2011026I2 (en) 2012-06-11
NO331183B1 (en) 2011-10-24
CA2335300C (en) 2008-10-07
HK1035534A1 (en) 2001-11-30
BR9911326A (en) 2001-04-03
CY2011010I1 (en) 2014-04-09
EP2272840B1 (en) 2012-08-22
NO20093217L (en) 2001-02-15
BRPI9911326B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
BE2011C028I2 (en) Macrocyclic analogs and methods of their use and preparation
CA2259148A1 (en) Solid oral dosage forms of valsartan
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
EP1193270A3 (en) Pyrrolobenzodiazepines
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
WO2001072728A3 (en) Novel piperazine derivatives
AU2001288686A1 (en) Improved cardiac function through administration of es cells
WO2001012202A3 (en) Use of chemical chelators as reversal agents for drug-induced neuromuscular block
EP2017269A3 (en) A pharmaceutical compodition comprising form II crystalline Ritonavir and a preparation thereof
WO2002032901A3 (en) Bridged piperazine derivatives
AU2001230898A1 (en) Formulations and methods for administration of pharmacologically or biologicallyactive compounds
AU5762099A (en) The preparation of (n)-substituted-hydroxycycloalkylamine derivatives
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
AU5368699A (en) Derivatives of triptolide, and preparation and uses thereof
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
CA2445620A1 (en) Tetracyclic compounds as pde5-inhibitors
AU3382001A (en) Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
WO2000064427A3 (en) Lamivudine containing pharmaceutical formulation
AU2001272490A1 (en) Use of galiella lactone
AU2001236361A1 (en) Treatment of asthma with lfm analogues
WO2001060801A3 (en) 9-alkylamino-1-nitroacridine derivatives
AU2002350212A1 (en) Pharmaceutically active compounds and methods of use thereof
HK1058761A (en) Compositions and methods for administration of pharmacologically active compounds